Literature DB >> 2405342

Variability of pulmonary function tests in cystic fibrosis.

P J Cooper1, C F Robertson, I L Hudson, P D Phelan.   

Abstract

The aim of this study was to define the within-subject variability for tests of respiratory function in patients with cystic fibrosis (CF) within the day, from day to day and from week to week. Twenty-eight patients with CF (aged 9-19 years) and 23 healthy height matched controls (aged 9-18 years) had measurements made of spirometry, lung volumes, maximal flows at three lung volumes and maximal inspiratory and expiratory pressures at the mouth. Testings were done on nine occasions, three times within a day, on consecutive days at one week intervals. Each individual's variability was summarized both as the within-subject coefficient of variation (WCV) and within-subject standard deviation (WSD). Means of WSD and median WCV are reported for both the patients with CF and normal subjects. The within-subject variability of VC, FEV1, TLC, RV, and RV/TLC was more appropriately assessed by the use of WSD rather than WCV. The WSDs in the CF group were significantly more variable (P less than 0.005) than in the normals for VC and FEV1. WCV best summarized within-subject variation for FEF25-75, FRC, V25, V50max and V75max for which the CF subjects were significantly more variable (P less than 0.005). Individuals' variability was very consistent, therefore assessment of significant change could be made more accurately by predetermining the variability of that individual, rather than using group data. We stress the importance to consider increased variability from day to day and week to week in the interpretation of change in lung function in patients with CF, and provide reference values for accurate interpretation of serial pulmonary function test results.

Entities:  

Mesh:

Year:  1990        PMID: 2405342     DOI: 10.1002/ppul.1950080107

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  19 in total

Review 1.  Asthma in cystic fibrosis.

Authors:  Ian M Balfour-Lynn
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 2.  "CF asthma": what is it and what do we do about it?

Authors:  I M Balfour-Lynn; J S Elborn
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

3.  Hypertonic saline inhalation in cystic fibrosis--salt in the wound, or sweet success?

Authors:  Beth Enderby; Iolo Doull
Journal:  Arch Dis Child       Date:  2007-03       Impact factor: 3.791

4.  Reply: Decline of Lung Function in Children with Sickle Cell Disease Is Not Associated with Restrictive Defects.

Authors:  Robyn T Cohen; Mark Rodeghier; Michael R DeBaun
Journal:  Ann Am Thorac Soc       Date:  2017-03

5.  Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis.

Authors:  I M Balfour-Lynn; N J Klein; R Dinwiddie
Journal:  Arch Dis Child       Date:  1997-08       Impact factor: 3.791

Review 6.  Treatment of severe small airways disease in children with cystic fibrosis: alternatives to corticosteroids.

Authors:  Adam Jaffe; Ian M Balfour-Lynn
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 7.  Human recombinant DNase in cystic fibrosis.

Authors:  A H Thomson
Journal:  J R Soc Med       Date:  1995       Impact factor: 5.344

8.  Perception of Pulmonary Function in Children with Asthma and Cystic Fibrosis.

Authors:  Erick Forno; Neethu Abraham; Daniel G Winger; Christian Rosas-Salazar; Geoffrey Kurland; Daniel J Weiner
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2018-09-17       Impact factor: 1.349

Review 9.  Timing of dornase alfa inhalation for cystic fibrosis.

Authors:  Ruth Dentice; Mark Elkins
Journal:  Cochrane Database Syst Rev       Date:  2016-07-26

10.  Comparative evaluation of chest radiography, low-field MRI, the Shwachman-Kulczycki score and pulmonary function tests in patients with cystic fibrosis.

Authors:  Angela Anjorin; Helga Schmidt; Hans-Georg Posselt; Christina Smaczny; Hanns Ackermann; Michael Deimling; Thomas J Vogl; Nasreddin Abolmaali
Journal:  Eur Radiol       Date:  2008-02-15       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.